Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug428 | Azithromycin Tablets Wiki | 0.41 |
| drug656 | Bromhexine 8 MG Wiki | 0.29 |
| drug354 | Ascorbic Acid Wiki | 0.29 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2246 | MRI Wiki | 0.29 |
| drug220 | Adenovirus Type-5 Vectored COVID-19 Vaccine Wiki | 0.29 |
| drug2159 | Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] Wiki | 0.29 |
| drug2744 | Oxygen supply Wiki | 0.29 |
| drug3382 | Ritonavir/lopinavir Wiki | 0.29 |
| drug214 | Ad5-nCoV Wiki | 0.29 |
| drug2604 | Non-enhanced CT scan of the chest Wiki | 0.29 |
| drug4789 | traditional communication tools Wiki | 0.29 |
| drug4033 | Tocilizumab Injection [Actemra] Wiki | 0.29 |
| drug1563 | Folic Acid Wiki | 0.29 |
| drug4123 | UCMSCs Wiki | 0.29 |
| drug1798 | Hydroxychloroquine Sulfate + Azythromycin Wiki | 0.29 |
| drug4771 | telemedicine Wiki | 0.29 |
| drug1797 | Hydroxychloroquine Sulfate + Azithromycin Wiki | 0.29 |
| drug2208 | Low-dose radiotherapy Wiki | 0.29 |
| drug1598 | GLS-1027 Wiki | 0.29 |
| drug1509 | Famotidine 20 MG Wiki | 0.20 |
| drug2200 | Low molecular weight heparin Wiki | 0.20 |
| drug907 | Chloroquine Sulfate Wiki | 0.20 |
| drug1081 | Corticosteroid Wiki | 0.20 |
| drug2070 | Ketogenic diet Wiki | 0.20 |
| drug4749 | standard of care Wiki | 0.17 |
| drug421 | Azithromycin Wiki | 0.14 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008589 | Meningococcal Infections NIH | 0.29 |
| D000257 | Adenoviridae Infections NIH | 0.29 |
| D008585 | Meningitis, Meningococcal NIH | 0.20 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008581 | Meningitis, Mening NIH | 0.20 |
| D007249 | Inflammation NIH | 0.10 |
| D003141 | Communicable Diseases NIH | 0.08 |
| D007239 | Infection NIH | 0.08 |
| D001172 | Arthritis, Rheumatoid NIH | 0.08 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.07 |
| D001168 | Arthritis NIH | 0.07 |
| D018352 | Coronavirus Infections NIH | 0.06 |
| D011014 | Pneumonia NIH | 0.06 |
| D004630 | Emergencies NIH | 0.05 |
| D012141 | Respiratory Tract Infections NIH | 0.05 |
| D016638 | Critical Illness NIH | 0.04 |
| D011024 | Pneumonia, Viral NIH | 0.03 |
| D014777 | Virus Diseases NIH | 0.03 |
| D013577 | Syndrome NIH | 0.03 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.02 |
| D055371 | Acute Lung Injury NIH | 0.02 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001287 | Meningitis HPO | 0.20 |
| HP:0001370 | Rheumatoid arthritis HPO | 0.08 |
| HP:0001369 | Arthritis HPO | 0.07 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002090 | Pneumonia HPO | 0.06 |
| HP:0011947 | Respiratory tract infection HPO | 0.05 |
Navigate: Correlations HPO
There are 12 clinical trials
In the current proposal, the investigators aim to investigate the virological and clinical effects of chloroquine treatment in patients with established COVID-19 in need of hospital admission. Patients will be randomized in a 1:1 fashion to standard of care or standard of care with the addition of therapy with chloroquine.
Description: Viral load assessed by real time polymerase chain reaction in oropharyngeal samples
Measure: Rate of decline in SARS-CoV-2 viral load Time: Baseline (at randomization) and at 96 hoursDescription: National Early Warning Score score determines the degree of illness of a patient. Scores range from 0-20, with a higher score representing further removal from normal physiology and a higher risk of morbidity and mortality.
Measure: Change in National Early Warning Score score Time: Baseline (at randomization) and at 96 hoursDescription: Transfer from regular ward to intensive care unit during index admission
Measure: Admission to intensive care unit Time: At all times after randomization during index admission (between admission and discharge, approximately 21 days)Description: All-cause mortality during index admission
Measure: In-hospital mortality Time: At all times after randomization during index admission (between admission and discharge, approximately 21 days)Description: Total days admitted to the hospital (difference between admission date and discharge date of index admission)
Measure: Duration of hospital admission Time: During index admission (between admission and discharge, approximately 21 days)Description: All-cause mortality assessed at 30 and 90 days
Measure: Mortality at 30 and 90 days Time: At follow-up 30 and 90 daysDescription: Percentage of subjects reporting each severity rating on a 7-point ordinal scale: Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation Hospitalized, on non-invasive ventilation or high flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen Not hospitalized, but unable to resume normal activities Not hospitalized, with resumption of normal activities
Measure: Clinical status Time: 14 days after randomizationDescription: Change in C-reactive protein concentrations from randomization to 96 hours after randomization
Measure: Change in C-reactive protein concentrations Time: Baseline (at randomization) and at 96 hoursDescription: Change in alanine aminotransferase concentrations from randomization to 96 hours after randomization
Measure: Change in alanine aminotransferase concentrations Time: Baseline (at randomization) and at 96 hoursDescription: Change in aspartate aminotransferase concentrations from randomization to 96 hours after randomization
Measure: Change in aspartate aminotransferase concentrations Time: Baseline (at randomization) and at 96 hoursDescription: Change in bilirubin concentrations from randomization to 96 hours after randomization
Measure: Change in bilirubin concentrations Time: Baseline (at randomization) and at 96 hoursDescription: Change in estimated glomerular filtration rate from randomization to 96 hours after randomization
Measure: Change in estimated glomerular filtration rate Time: Baseline (at randomization) and at 96 hoursDescription: Change in cardiac troponin concentrations from randomization to 96 hours after randomization
Measure: Change in cardiac troponin concentrations Time: Baseline (at randomization) and at 96 hoursDescription: Change in natriuretic peptide concentrations from randomization to 96 hours after randomization
Measure: Change in natriuretic peptide concentrations Time: Baseline (at randomization) and at 96 hoursThis is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons with laboratory confirmed SARS-CoV-2 or clinically suspected COVID-19. Eligible participants will be enrolled and randomized to receive the intervention or placebo at the level of the household (all eligible participants in one household will receive the same intervention).
Description: Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection from self-collected samples collected daily for 14 days
Measure: Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection Time: Day 1 through Day 14 after enrolmentDescription: Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection from self-collected samples collected at study exit
Measure: Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection Time: Day 28 after enrolmentDescription: Safety and tolerability of Hydroxychloroquine as SARS-CoV-2 PEP in adults
Measure: Rate of participant-reported adverse events Time: 28 days from start of Hydroxychloroquine therapyDescription: PCR-confirmed COVID-19 diagnosis
Measure: Incidence rates of COVID-19 through study completion Time: 28 days from enrolmentThis is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D5) and azithromycin (500 mg/ 5 days) to treat moderate to severe COVID-19 pneumonia.
Description: Evaluation of change from baseline. Kaplan-meier method will be used.
Measure: Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability Time: 28 daysDescription: Evaluation of change in viral load
Measure: Viral load Time: Day 6Description: Time for normalization of body temperature, respiratory rate and cough relief
Measure: Change in Clinical Condition Time: 28 daysDescription: Time to wean off oxygen supplementation and / or invasive / non-invasive ventilatory support;
Measure: Evolution of Acute Respiratory Syndrome Time: 28 daysDescription: Time to be discharged from hospital
Measure: Hospital discharge Time: 28 daysDescription: Evaluation of change in acute respiratory syndrome
Measure: Rate of mortality within 28-days Time: 28 daysThis is a three-arm randomized trial comparing the efficacy of single agent hydroxychloroquine to the combination of hydroxychloroquine and azithromycin, and to a delayed hydroxychloroquine regimen, which will serve as a contemporaneous Day 1-6 supportive care control, in eliminating detectable SARS-CoV-2 on day 6 following the initiation of treatment in order to determine which regimen is more effective.
Description: Will be assessed at day six compared to baseline between hydroxychloroquine sulfate alone and hydroxychloroquine sulfate plus azithromycin to treat COVID-19.
Measure: Changes in patients viral load Time: Baseline, day 3 and day 6Description: A second concurrent comparison will evaluate change in viral load at day 6 between hydroxychloroquine sulfate alone and supportive care.
Measure: Second evaluation of changes in patients viral load Time: Day 6Description: Time to resolution of symptoms
Measure: Symptom questionnaire Time: up to 6 monthsDescription: Change in the fever curve resulting in shorter time to afebrile for 48 hours
Measure: Fever assessment Time: up to 10 daysDescription: Body temperature will be measured in degrees Fahrenheit using an automated thermometer which will be provided to the patient 4 times per day.
Measure: Vital Signs - Body Temperature Time: up to 10 daysDescription: Time to discharge (If hospitalized)
Measure: Discharge Time: up to 6 monthsDescription: Time to recovery (back to school, work, etc)
Measure: Recovery Time: up to 6 monthsDescription: As measured by standard metrics
Measure: Assessment of agent toxicity Time: up to 10 daysDescription: Collection of Oropharynx swabs for viral load and microbiome analysis
Measure: Oropharynx swab sample collections Time: up to 10 daysDescription: Collection of blood for viral load and microbiome analysis
Measure: Blood Sample collections Time: up to 10 daysDescription: Decrease in virus shedding in nasopharyngeal secretions such as Ferritin, D-dimer, CRP, Troponin and LDH
Measure: Viral shedding assessment - nasopharyngeal secretions Time: up to 10 daysDescription: Decrease in virus shedding in serology such as Ferritin, D-dimer, CRP, Troponin and LDH
Measure: Viral shedding assessment - serology Time: up to 10 daysDescription: Measurement of cytokines in blood
Measure: Cytokines in blood Time: up to 10 daysThis study will investigate the security and efficacy of a daily low dose of hydroxychloroquine, in preventing the development of the disease from COVID-19 in Health Care Workers at a National Institute of Health In Mexico City.
Description: https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf, this scale reflects a range from uninfected to dead, where 0 is "no clinical or virological evidence of infection", 1 is "no limitation of activities", 2 is "limitation of activities", 3 is "hospitalized, no oxygen therapy", 4 is "oxygen by mask or nasal prongs", 5 is "non-invasive ventilation or high-flow oxygen", 6 is "intubation and mechanical ventilation", 7 is "ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)", and 8 is "death".
Measure: Polymerase chain reaction assay (PCR) negative at day 0 plus negative serological panel for COVID-19 antibodies at enrolment. Time: Day 0Description: https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf, this scale reflects a range from uninfected to dead, where 0 is "no clinical or virological evidence of infection", 1 is "no limitation of activities", 2 is "limitation of activities", 3 is "hospitalized, no oxygen therapy", 4 is "oxygen by mask or nasal prongs", 5 is "non-invasive ventilation or high-flow oxygen", 6 is "intubation and mechanical ventilation", 7 is "ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)", and 8 is "death".
Measure: Polymerase chain reaction assay (PCR) negative at day 30. Time: Day 30Description: https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf, this scale reflects a range from uninfected to dead, where 0 is "no clinical or virological evidence of infection", 1 is "no limitation of activities", 2 is "limitation of activities", 3 is "hospitalized, no oxygen therapy", 4 is "oxygen by mask or nasal prongs", 5 is "non-invasive ventilation or high-flow oxygen", 6 is "intubation and mechanical ventilation", 7 is "ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)", and 8 is "death".
Measure: Polymerase chain reaction assay (PCR) negative at day 60. Time: Day 60This Phase III trial four treatment strategies non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, Participants will receive hydroxychloroquine or chloroquine with or without azithromycin.
Description: Time (hours) from randomization to recovery defined as 1) absence of fever, as defined as at least 48 hours since last temperature ≥ 38.0°C without the use of fever-reducing medications AND 2) absence of symptoms of greater than mild severity for 24 hours AND 3) not requiring supplemental oxygen beyond pre-COVID baseline AND 4) freedom from mechanical ventilation or death
Measure: Hours to recovery Time: 42 daysDescription: Time to resolution of fever defined as at least 48 hours since last temperature ≥ 38.0°C without the use of fever-reducing medications
Measure: Time fever resolution Time: 42 daysThe current outbreak of COVID-19 caused by SARS-CoV-2 is a global health emergency with a case fatality rate so far approximately 4% and a growing number of confirmed cases (>9500) in Germany. There is no data available on the efficacy of antiviral agents for the treatment of COVID-19. In vitro data show that hydroxychloroquine can inhibit SARS-CoV-2 replication and anecdotal reports from COVID-19 patients in China and France suggest that chloroquine or hydroxychloroquine is a good candidate for treatment. In the French study a favourable effect was seen when hydroxychloroquine was used together with azithromycin in a small series of COVID-19 patients. However, so far all published evidence is based on non-controlled use of hydroxychloroquine. We propose to conduct a placebo-controlled trial in COVID-19 patients with mild to moderate disease in Germany to assess virological efficacy, tolerability and safety of hydroxychloroquine in the treatment of COVID-19. The objective of this trial is to identify an effect of hydroxychloroquine on viral clearance in vivo. This data will inform practice for the design of larger trials on clinical efficacy of hydroxychloroquine in the treatment and post-exposure prophylaxis of COVID-19.
Description: Viral clearance defined as time to sustained SARS-CoV-2-specific RNA copy number ≤100, measured by real time reverse-transcription polymerase chain reaction RT-PCR in throat swabs.
Measure: Effect of HCQ on in vivo viral clearance Time: 6 monthsThis is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D7) and azithromycin (500 mg/ 5 days) to treat mild ambulatory COVID-19 patients.
Description: Ordinal scale (7 points ordinal scale that measures illness severity over time)
Measure: Change in Clinical Condition Time: 28 daysDescription: Number of patients that needed to be hospitalized
Measure: Hospitalization Time: 28 daysDescription: Time for normalization of body temperature
Measure: Change in Clinical Condition Time: 28 daysDescription: Time for normalization of of respiratory rate
Measure: Change in Clinical Condition Time: 28 daysDescription: Time for cough relief
Measure: Change in Clinical Condition Time: 28 daysDescription: Evaluation of change in acute respiratory syndrome
Measure: Rate of mortality within 28-days Time: 28 daysDescription: Subgroup analysis by comorbidities
Measure: Change in Clinical Condition related to comorbidity Time: 28 daysThis is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching goal of this study is to assess the effectiveness of interventions on the incidence of lower respiratory tract infection (LRTI) progression among high-risk adult outpatients with SARS-CoV-2 infection to inform public health control strategies.
Description: Resting blood oxygen saturation (SpO2<93%) level sustained for 2 readings 2 hours apart and presence of subjective dyspnea or cough
Measure: Lower respiratory tract infection (LRTI) rates Time: 28 days from enrolmentDescription: Cumulative incidence of hospitalization or mortality
Measure: Incidence of hospitalization or mortality Time: Day 28 after enrolmentDescription: Time to clearance of nasal SARS-CoV-2, defined as 2 consecutive negative swabs
Measure: Change in upper respiratory viral shedding Time: Day 1 through Day 14 after enrolmentDescription: COVID-19 symptoms are based on the following criteria: At least TWO of the following symptoms: Fever (≥ 38ºC), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s), OR At least ONE of the following symptoms: cough, shortness of breath or difficulty breathing, OR Severe respiratory illness with at least 1 of the following: Clinical or radiological evidence of pneumonia, OR Acute respiratory distress syndrome (ARDS), OR LRTI, defined by resting SpO2<93% sustained for 2 readings 2 hours apart AND presence of subjective dyspnea or cough Death or COVID-19-related hospitalizations will count as a failure to resolve symptoms.
Measure: COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only] Time: Day 1 through Day 14 after enrolmentDescription: Serious adverse events (including death and hospitalization) and adverse events resulting in treatment discontinuation
Measure: Rate of participant-reported adverse events Time: 28 days from enrolmentDescription: Duration of hospitalization among persons who become hospitalized with COVID-19 disease
Measure: COVID-19-related hospitalization days Time: 28 days from enrolmentDescription: Peak score on WHO Ordinal Scale for Clinical Improvement Peak score on modified inFLUenza patient-reported outcome (Flu-PRO) instrument
Measure: Rate of disease severity Time: Day 1 through Day 14 after enrolmentDescription: Proportion of days with SARS-CoV-2 detected from mid-nasal swabs by PCR Median quantity of SARS-CoV-2 detected from mid-nasal swabs by PCR
Measure: Viral shedding rates Time: Day 1 through Day 14 after enrolmentDescription: PK-evaluable participants will have post-hoc individual concentration profiles and exposure estimates determined for exploratory exposure-response analyses against primary and secondary efficacy and safety endpoints
Measure: Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only] Time: 28 days from enrolmentThe Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) has been identified in Wuhan, China, which causes severe pulmonary complications and flu syndrome, which has spread rapidly to all continents. Approximately 25% of hospitalized patients require treatment in intensive care units and 10% require mechanical ventilation. The diagnosis is made by the molecular polymerase chain reaction test. However, diagnostic tests are limited. The clinical care of the patient with COVID-19 is similar to that of patients with severe infectious respiratory complications, consisting of support and oxygen supplementation. Several medications have been tested as remdesivir, a pro-drug nucleoside, which acts by inhibiting viral RNA transcription, although a recently published study has shown no benefit. China recently approved the use of favipiravir, an antiviral used for influenza, as an experimental therapy for COVID-19. Hydroxychloroquine is a drug with great potential treatment, as it can inhibit the pH-dependent steps of replication of various viruses, with a potent effect on SARS-CoV infection and spread. In this way, the present study will evaluate the safety and efficacy of the hydroxychloroquine in patients with symptomatic SARS-Cov2.
Description: The individual response rate regarding the World Health Organization Ordinal Scale assessment from basal to 14th Day.
Measure: Individual response rate Time: 14 days after randomizationDescription: All-cause mortality rates at Day 28th after randomization
Measure: All-cause mortality Time: 28 days after randomizationDescription: Number of days that the patient was on mechanical ventilation which was under ventilation from basal line
Measure: Duration of mechanical ventilation Time: baselineDescription: Proportion of patients who do not receive mechanical ventilation at the beginning of the study and then needed mechanical ventilation during hospitalization.
Measure: Proportion of patients which needed mechanical ventilation during study Time: hospitalization within 28 daysDescription: The ordinal scale is an assessment of the clinical status at the first clinical evaluation in a clinical study. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities.
Measure: World Health Organization (WHO) Ordinal scale Time: 28 days after inclusion and compared to baselineDescription: Length of hospital stay in days for hospitalization
Measure: Duration of hospitalization Time: hospitalization within 28 daysDescription: Rates of drug discontinuation in all causes under study
Measure: Rates of drug discontinuation Time: hospitalization within 28 daysDescription: Rates of serious adverse events
Measure: Rates of serious adverse events Time: Day 14thFew studies have reported the efficacy of HCQ in reducing the viral load and improving the severity of symptoms in hospitalized COVID-19 cases with serious respiratory infection. However, the prophylactic benefits of HCQ has not been clearly defined yet.
Description: Time to reach normal body temperature (TNBT), ≤37.50 C
Measure: Time to reach normal body temperature Time: 1 monthDescription: Development of fever and/or other symptoms of COVID-19 during the 1 month of the HCQ therapy
Measure: Development of COVID-19 symptoms during HCQ preventive therapy in staff Time: 1 monthDescription: Viral RNA test results at day 6 will be compared between the HCQ vs no-HCQ group
Measure: COVID-19 test result at follow-up in patients Time: 6 daysDescription: Worsening of symptoms in COVID-19 patients requiring artificial ventilation during the study period
Measure: Worsening of symptoms in COVID-19 patients Time: 1 monthLow radiation doses produce anti-inflammatory effects, which may be useful in the treatment of respiratory complications of COVID-19. This type of treatment is non-invasive and therefore, a priori, it can be used in all types of patients. Main objective: To evaluate the efficacy of low-dose lung irradiation as an adjunctive treatment in interstitial pneumonia in patients with COVID-19 by improving the PAFI O2 by 20% measured 48h after treatment with respect to the pre baseline measurement. -irradiation.
Description: To evaluate the efficacy of low-dose pulmonary irradiation as an adjunctive treatment in interstitial pneumonia in patients with COVID-19 by improving the PAFI O2 by 20% measured 48h after treatment with respect to baseline pre-irradiation measurement. . In cases of impossibility the SaFiO2 will be determined
Measure: Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20% Time: Day 2 after interventional radiotherapyDescription: Lung toxicity measured according to CTCAEv5
Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 Time: Day 30 and day 90 after interventional radiotherapyDescription: Chest CT
Measure: Change of the radiological image Time: Days 7 and day 30 after interventional radiotherapyDescription: Death of any cause
Measure: Overall mortality Time: Day 15 and Day 30 after interventional radiotherapyDescription: Interleukins IL-6, IL-10, IL-1, IL-2, IL-8 (pg/ml)
Measure: Measure of pro-inflammatory interleukins Time: Days 1, day 4 and day 7 after interventional radiotherapyDescription: TGF-β (ng/ml)
Measure: Measure of trasforming growth factor (TGF-b) Time: Days 1, day 4 and day 7 after interventional radiotherapyDescription: TNF-α (pg/ml)
Measure: Measure of tumor necrosis factor alpha (TNF-a) Time: Days 1, day 4 and day 7 after interventional radiotherapyDescription: Overexpression of L-, E-, and P-selectin
Measure: Determining overexpression of pro-inflammatory selectin Time: Days 1, day 4 and day 7 after interventional radiotherapyDescription: Overexpression of ICAM-1, VCAM
Measure: Determining cell adhesion molecules (CAMs) Time: Days 1, day 4 and day 7 after interventional radiotherapyDescription: PON-1(paraoxonase and arylesterase activity) (IU/ml)
Measure: Measure of marker of oxidative stress PON-1 Time: Days 1, day 4 and day 7 after interventional radiotherapyAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports